SCYNEXIS to Showcase Second Generation Antifungal SCY-247
SCYNEXIS, Inc. (NASDAQ: SCYX), a pioneering biotechnology company, is excited to present its preclinical efficacy and pharmacokinetic data on SCY-247, a second-generation antifungal candidate, at IDWeek 2024. This significant event will occur from October 16-19, 2024, where healthcare professionals and scientists gather to discuss advances in infectious disease management. The presentations focus on crucial research aimed at addressing the urgent need for innovative treatments to combat drug-resistant infections.
Scheduled Presentations of SCY-247
During IDWeek 2024, SCYNEXIS has outlined two key presentations that will delve into the capabilities of SCY-247.
Oral Presentation on SCY-247 Efficacy
The first presentation will feature an oral discussion titled "Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections." This presentation is scheduled for Thursday, October 17, 2024, at 10:45 AM PDT. Attendees will gain insights into the promising effects of SCY-247 in preclinical models, guided by David A. Angulo, M.D., the President and CEO of SCYNEXIS.
Poster Presentation Details
The second presentation will be a poster session, which takes place on Friday, October 18, 2024, from 12:15 PM to 1:30 PM PDT. This session, titled "SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction Potential," will also be led by Dr. Angulo. This presentation aims to highlight the extensive tissue distribution and favorable pharmacokinetic profile of SCY-247, marking its potential as a novel therapeutic option in the antifungal landscape.
Understanding SCY-247’s Mechanism and Potential
SCY-247 is at the forefront of antifungal innovation, belonging to a unique class of glucan synthase inhibitors known as triterpenoids (or fungerps). This compound is being developed to counter the threats posed by antimicrobial resistance (AMR) in systemic fungal infections that often lead to high mortality rates. As the first new class of antifungal agents approved since 2001, triterpenoids aim to provide significant clinical advantages with their dual forms of intravenous and oral administration.
SCYNEXIS: Dedicated to Innovation in Antifungals
At its core, SCYNEXIS is dedicated to creating revolutionary treatments that assist patients globally in overcoming drug-resistant infections. SCYNEXIS has already made headway with its first antifungal product, Ibrexafungerp, which has been successfully approved by the U.S. Food and Drug Administration (FDA) for treating vulvovaginal candidiasis. The success of Ibrexafungerp lays a strong foundation for SCY-247, currently in pre-IND development, showcasing broad-spectrum antifungal activity against machine resistant fungal pathogens.
If the FDA Grants Critical Designations
There is anticipatory excitement surrounding the potential designations SCY-247 may receive from the FDA, including Qualified Infectious Disease Product (QIDP) and Fast Track pathways for both its oral and intravenous formulations. These designations would expedite the development of SCY-247, allowing for quicker access to patients in need of effective treatments against resistant fungal infections.
Frequently Asked Questions
What is SCY-247?
SCY-247 is a second-generation antifungal agent currently in preclinical development that targets drug-resistant fungal infections.
When will SCYNEXIS present findings on SCY-247?
Presentations will be held during IDWeek 2024 from October 16-19, including oral and poster sessions highlighting the compound's efficacy.
Who is presenting SCY-247 research?
The research will be presented by Dr. David A. Angulo, the President and CEO of SCYNEXIS.
What makes SCY-247 significant?
SCY-247 represents a novel class of antifungal compounds with broad-spectrum activity against resistant pathogens, offering new hope for treatment options.
How is SCYNEXIS advancing antifungal treatments?
SCYNEXIS is dedicated to developing innovative antifungal therapies, with SCY-247 being a key component of their expanding portfolio aimed at treating difficult infections.
